<DOC>
	<DOCNO>NCT02735928</DOCNO>
	<brief_summary>Patients first recurrent resistance ovarian cancer disease progression peritoneal carcinomatosis undergo PIPAC procedure . The primary end point determine clinical benefit rate ( CBR ) pressurize intraperitoneal aerosol chemotherapy combination cisplatin doxorubicin .</brief_summary>
	<brief_title>Pressurized Intraperitoneal Aerosol Chemotherapy ( PIPAC ) Applied Platinum-Resistant Recurrence Ovarian Tumor</brief_title>
	<detailed_description>This study aim investigate therapeutic efficacy PIPAC use cisplatin doxorubicin woman first recurrent resistance ovarian cancer disease progression peritoneal carcinomatosis . The primary objective study determine Clinical Benefit Rate ( CBR ) accord RECIST/GCOG criterion three cycle PIPAC PIPAC cisplatin doxorubicin</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Patients affect first second platinum resistant epithelial ovarian tumor recurrence . ECOGperformance status ≤ 3 . Adequate respiratory , hepatic , cardiac , kidney bone marrow function ( absolute neutrophil count &gt; 1500 / mm3 , platelet &gt; 150 000/μl , creatinine clearance &gt; 60 mL / min accord Cockroft formula ) . Patientcompliant psychologically able follow trial procedure . Nonepithelial ovarian cancer borderline ovarian tumor . Pregnancy breastfeed . Patients affect major depressive disorder even treatment minor mood disorder . Patients severe impairment respiratory , hepatic renal function . Patients cardiac , neurological metabolic uncontrolled pharmacologically disease Patients bowel obstruction . Inadequate bone marrow , liver , kidney function . No clearperitoneal disease surgical exploration . Patients ascites &gt; 2000 cc ( CTScan ) Patients already make third line chemotherapy .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>